GlassScriptPhysician profile
Lakshmi Gordon
NPI 1053303891
$4,145.16
in general payments reported to CMS, 2019-2025
31 companies · $527 in 2025
The $527 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $462 · 2021: $709 · 2022: $622 · 2023: $639 · 2024: $710 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.07 | 2019-2024 | |
| Coopersurgical, INC. | $382.28 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Mayne Pharma Commercial LLC | $342.97 | 2021-2025 | |
| Evofem Biosciences, INC. | $298.06 | 2021-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $259.04 | 2019-2025 | Slynd |
| Therapeuticsmd, INC. | $256.05 | 2019-2022 | |
| Amgen INC. | $250.00 | 2019-2020 | |
| Aspira Women'S Health INC | $171.69 | 2021-2024 | Ova1 |
| Shield Therapeutics INC | $155.68 | 2022-2025 | |
| Pfizer INC. | $151.77 | 2019-2023 | |
| Agile Therapeutics, INC. | $147.73 | 2022-2024 | Twirla |
| Avion Pharmaceuticals | $140.53 | 2021-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $129.32 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $128.14 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $126.67 | 2020-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $89.57 | 2019-2021 | |
| Daiichi Sankyo INC. | $87.30 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $86.25 | 2022-2023 | Monoferric |
| Organon LLC | $76.46 | 2024-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $68.57 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Amag Pharmaceuticals, INC. | $42.19 | 2019 | |
| Myovant Sciences INC. | $39.85 | 2021-2022 | |
| Urovant Sciences INC | $35.41 | 2022 | |
| Vertical Pharmaceuticals, LLC | $33.20 | 2019 | |
| Allergan, INC. | $25.43 | 2019-2020 | |
| Trevena, INC. | $23.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $22.48 | 2023 | Quviviq |
| Duchesnay USA Incorporated | $13.62 | 2019 | |
| Mission Pharmacal Company | $12.21 | 2021 | |
| Merck Sharp & Dohme LLC | $11.76 | 2019 | |
| Novo Nordisk INC | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakshmi Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.